Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaPatient-level factorsProvider-level factorsRenal cell carcinomaIndex dateRace/ethnicityInitial diagnosisCell carcinomaRisk ratioState cancer registry dataNumber of comorbiditiesMore comorbid conditionsPatient-level predictorsCancer registry dataProportion of daysProvider-level variablesPrescription drug filesMedian PDCMRCC diagnosisMRCC patientsPatient characteristicsPharmacy claimsComorbid conditionsMetastatic diagnosisMedical oncologyOral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).
Dinan M, Wilson L, Greiner M, Spees L, Pritchard J, Zhang T, Kaye D, George D, Scales C, Wheeler S. Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 280-280. DOI: 10.1200/jco.2021.39.6_suppl.280.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsDisease-specific survivalRenal cell carcinomaCell carcinomaPatient populationSEER-Medicare patientsDisease-specific mortalityNumber of comorbiditiesOlder patient populationProgression-free survivalReal-world adherenceRandomized clinical trialsTreatment of patientsAnalysis of patientsProportion of daysRCC-specific mortalityMinimum effective doseSignificant reductionOAA therapyCause mortalityElderly patientsFavorable survivalMetastatic RCCMultivariable analysis